Cetylpyridinium
Trials 32
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 03 trials | ||||||
| Phase 0 | NCT04931004 | Jul 2021 → May 2022 | COVID-19 | Rutgers, The State University of New Jersey | Completed | No outcome recorded |
| Phase 0 | NCT02575235 | Oct 2015 → Jul 2016 | muscular atrophy | Seoul National University Hospital | Completed | No outcome recorded |
| Phase 0 | NCT02297997 | Nov 2014 → Nov 2015 | muscular atrophy | Seoul National University Hospital | Completed | No outcome recorded |
| Phase 15 trials | ||||||
| Phase 1 | NCT06859281 | Dec 2024 → Dec 2026 expected | pharyngitis | Valenta Pharm JSC | Recruiting | No outcome recorded |
| Phase 1 | NCT06857890 | Dec 2024 → Dec 2026 expected | pharyngitis | Valenta Pharm JSC | Recruiting | No outcome recorded |
| Phase 1 | NCT05924906 | Oct 2023 → Apr 2026 overdue | neoplasm | Suzhou Neologics Bioscience Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT03706781 | Nov → Dec 2017 | — | Angelini Pharma | Completed | No outcome recorded |
| Phase 1 | NCT03154021 | Aug 2017 → Mar 2018 | gingivitis, smooth surface dental caries | University of Florida | Completed | No outcome recorded |
| Phase 24 trials · 1 missed | ||||||
| Phase 2 | NCT04409873 | Mar 2021 → Sep 2022 | COVID-19, disorder of pharynx | University of California, San Francisco | Terminated | Missed primary Stop: Enrollment |
| Phase 2 | NCT02788786 | Jun → Nov 2016 | periodontitis | Johns Hopkins Bloomberg School of Public Health | Completed | No outcome recorded |
| Phase 2 | NCT02194023 | Sep 2011 → Jul 2013 | smooth surface dental caries | Universitat Internacional de Catalunya | Completed | No outcome recorded |
| Phase 2 | NCT00453271 | Jan 2007 → Oct 2008 | tinea unguium | NanoBio Corporation | Completed | No outcome recorded |
| Phase 38 trials | ||||||
| Phase 3 | NCT07553286 | Oct 2026 → Dec 2028 expected | fetal growth restriction, periodontal disorder | Johns Hopkins Bloomberg School of Public Health | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07398846 | Jan → Apr 2026 | — | Colgate Palmolive | Completed | No outcome recorded |
| Phase 3 | NCT07263698 | Dec 2025 → Feb 2026 | gingivitis | Colgate Palmolive | Completed | No outcome recorded |
| Phase 3 | NCT06479226 | Jun → Oct 2022 | — | Colgate Palmolive | Completed | No outcome recorded |
| Phase 3 | NCT07351370 | Jan → Jul 2022 | periodontal disorder | Dental School | Completed | No outcome recorded |
| Phase 3 | NCT06770114 | Oct 2021 → May 2022 | gingivitis | Colgate Palmolive | Completed | No outcome recorded |
| Phase 3 | NCT00729599 | Jul → Aug 2008 | — | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT00687037 | Jan → Feb 2008 | — | Sanofi | Completed | No outcome recorded |
| Phase 46 trials | ||||||
| Phase 4 | NCT07807397 | Sep 2026 → Sep 2027 expected | dental caries, gingivitis | Colgate Palmolive | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07619729 | May 2026 → Jan 2028 expected | dental caries, periodontal disorder, type 2 diabetes mellitus | Colgate Palmolive | Enrolling by invitation | No outcome recorded |
| Phase 4 | NCT05802628 | Apr 2023 | acute pharyngitis, gingivitis | Peking University People's Hospital | Completed | No outcome recorded |
| Phase 4 | NCT03219840 | Oct 2017 → Sep 2018 | gingivitis | The University of Texas Health Science Center, Houston | Completed | No outcome recorded |
| Phase 4 | NCT03179735 | Jun 2017 → Mar 2018 | gingivitis | University of Taubate | Unknown | No outcome recorded |
| Phase 4 | NCT07211061 | Sep → Nov 2011 | gingivitis | Procter and Gamble | Completed | No outcome recorded |
| Phase not applicable6 trials · 1 met primary · 1 missed | ||||||
| — | NCT07490873 | Jan → Jul 2026 | — | University of Baghdad | Completed | No outcome recorded |
| — | NCT06660069 | Nov 2024 → Mar 2025 | gingivitis, smooth surface dental caries | HALEON | Completed | Met primary |
| — | NCT06251089 | Nov 2023 → Aug 2024 | pharyngitis | Dentaid SL | Completed | No outcome recorded |
| — | NCT04707742 | Jun 2020 → Sep 2021 | COVID-19 | FISABIO Foundation | Completed | Missed primary |
| — | NCT02644135 | Jan → Jun 2013 | — | University Hospitals Cleveland Medical Center | Completed | Mixed |
| — | NCT01549587 | Feb 2012 → Feb 2014 | gingivitis, pregnancy disorder | Procter and Gamble | Completed | No outcome recorded |
| Comparator or background therapy13 trials | ||||||
| Phase 1/2 | NCT01580943 Comparator | Oct 2011 | smooth surface dental caries | University of Porto | Completed | No outcome recorded |
| Phase 1/2 | NCT00885599 Comparator | Jun 2009 → Jun 2010 | gingivitis | Shaare Zedek Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT04584684 Comparator | Dec 2020 → Oct 2021 | COVID-19 | University of North Carolina, Chapel Hill | Terminated | No outcome recorded |
| Phase 2/3 | NCT02756377 Comparator | May 2014 → Apr 2015 | periodontal disorder | Islamic Azad University, Sanandaj | Completed | No outcome recorded |
| Phase 3 | NCT06607172 Comparator | Sep → Oct 2024 | gingivitis | Colgate Palmolive | Completed | No outcome recorded |
| Phase 3 | NCT02193165 Comparator | Jul → Aug 2014 | gingivitis | Colgate Palmolive | Completed | No outcome recorded |
| Phase 3 | NCT02931357 Comparator | Sep 2013 | tooth disorder | Ricerfarma S.r.l | Completed | No outcome recorded |
| Phase 3 | NCT01265446 Background | Dec 2010 → Apr 2011 | — | Novartis | Completed | Missed primary |
| Phase 4 | NCT07489924 Comparator | Jan 2023 → Jul 2025 overdue | periodontitis, type 2 diabetes mellitus | University of Colima | Active not recruiting | No outcome recorded |
| Phase 4 | NCT04721457 Comparator | Jan → Mar 2021 | COVID-19 | King Abdulaziz University | Completed | No outcome recorded |
| Phase 4 | NCT02360995 Comparator | Jun → Aug 2014 | gingivitis | Colgate Palmolive | Completed | No outcome recorded |
| — | NCT06966817 Comparator | May 2024 → Jun 2025 overdue | — | University of Health Sciences | Enrolling by invitation | No outcome recorded |
| — | NCT04383236 Comparator | Dec 2016 → Oct 2018 | aphthous stomatitis | Reham Lotfy Aggour | Completed | No outcome recorded |
Evidence & citations 26 cited values
Every value below carries the sentence it was read from. 49 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Cetylpyridinium | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03706781 ↗ |
| Known as | Ceepryn | ChEMBL registry synonym — accepted as the source's own label CHEMBL305906 ↗ |
| Known as | Cepacol | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00885599 ↗ |
| Known as | CETYLPYRIDINIUM BROMIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL305906 ↗ |
| Known as | Cetylpyridinium chloride hydrate | ChEMBL registry synonym — accepted as the source's own label CHEMBL305906 ↗ |
| Known as | Cetylpyridinium chloride monohydrate | ChEMBL registry synonym — accepted as the source's own label CHEMBL305906 ↗ |
| Known as | cetylpyridinium-chloride | “BACKGROUND: This single-center, randomized controlled trial aimed to determine the effectiveness of a novel, biofilm-disrupting, mouth rinse that combines Cetylpyridinium...” PMID 36324127 ↗ Nov 202241“This is a multi-centre, blinded, parallel-group, placebo-controlled randomised clinical trial that tests the effect of four mouthwashes (cetylpyridinium chloride,...” PMID 34937855 ↗ Dec 2021 “ARMS-I is patented novel formulation for the prevention and treatment of influenza, comprising a broad-spectrum antimicrobial agent (cetylpyridinium chloride, CPC) and...” PMID 28088167 ↗ Jan 2017 “It was evidenced that cetylpyridinium-chloride (CPC) mouthwash could inhibit SARS-COV-2 activity and reduce salivary viral load, thus reducing SARS-CoV-2 transmission.” PMID 37985697 ↗ Nov 2023 “0.12% Chlorhexidine Digluconate and 0.05% Cetylpyridinium Chloride vs Probiotics (Lactobacillus Reuteri Prodentis) on Porphyromonas Gingivalis.” NCT07489924 ↗ “new 0.05% Cetylpyridinium chloride (CPC) mouthrinse formulations containing 0.12% or 0.03% chlorhexidine digluconate (CHX)” NCT02194023 ↗ “Lozenges containing lidocaine and cetylpyridinium chloride (CPC) are commonly used for the treatment of sore throat.” PMID 30541606 ↗ Dec 2018 “Over the counter: Crest Pro-Health Multi-Protection (Crest, USA) contains cetylpyridinium chloride (C21H38ClN)” NCT04409873 ↗ “Effect of Cetylpyridinium Chloride (CPC) Rinse in Viral Upper Respiratory Tract Infections (vURTI)” NCT06251089 ↗ “0,12% chlorhexidine and 0,05% cetyl-pyridinium chloride mouth rinse (Perio-aid®)” NCT01580943 ↗ “Each 100 g contains: Lidocaine HCI 2.0g. Cetylpyridinium chloride 0.1 g.” NCT04383236 ↗ |
| Known as | Chlorure de cetylpyridinium | ChEMBL registry synonym — accepted as the source's own label CHEMBL305906 ↗ |
| Known as | Cloruro de cetilpiridinio | ChEMBL registry synonym — accepted as the source's own label CHEMBL305906 ↗ |
| Known as | CPC | “BACKGROUND: This single-center, randomized controlled trial aimed to determine the effectiveness of a novel, biofilm-disrupting, mouth rinse that combines Cetylpyridinium...” PMID 36324127 ↗ Nov 202216“It was evidenced that cetylpyridinium-chloride (CPC) mouthwash could inhibit SARS-COV-2 activity and reduce salivary viral load, thus reducing SARS-CoV-2 transmission.” PMID 37985697 ↗ Nov 2023 “Participants will rinse with 15 mL alcohol-free cetylpyridinium chloride (CPC) 0.05% mouthwash (Kin B5) for 30 seconds twice daily for 7 days.” NCT07490873 ↗ “Vigorously rinse with 15 ml of the 0.075% cetylpyridinium chloride (CPC) (Colgate Total; Colgate-Palmolive, Guildford, UK) for 30 s” NCT04721457 ↗ “new 0.05% Cetylpyridinium chloride (CPC) mouthrinse formulations containing 0.12% or 0.03% chlorhexidine digluconate (CHX)” NCT02194023 ↗ “Lozenges containing lidocaine and cetylpyridinium chloride (CPC) are commonly used for the treatment of sore throat.” PMID 30541606 ↗ Dec 2018 “Effect of Cetylpyridinium Chloride (CPC) Rinse in Viral Upper Respiratory Tract Infections (vURTI)” NCT06251089 ↗ “gargling with a cetylpyridinium chloride (CPC) (0.075%) and zinc containing alcohol free rinse” NCT06479226 ↗ “daily antiseptic oral rinse (alcohol-free cetylpyridinium chloride (CPC) (0.075%))” NCT07553286 ↗ “cetylpyridinium chloride (CPC), zinc lactate and sodium fluoride Mouthwash” NCT07263698 ↗ “0.075% Cetylpyridinium Chloride (CPC) and 0.28% zinc lactatmouthwashe” NCT07398846 ↗ |
| Known as | Gppe dental rinse | ChEMBL registry synonym — accepted as the source's own label CHEMBL305906 ↗ |
| Known as | Gppe oral liq | ChEMBL registry synonym — accepted as the source's own label CHEMBL305906 ↗ |
| Known as | Merocet | ChEMBL registry synonym — accepted as the source's own label CHEMBL305906 ↗ |
| Known as | Merocets | ChEMBL registry synonym — accepted as the source's own label CHEMBL305906 ↗ |
| Known as | Merocets plus | ChEMBL registry synonym — accepted as the source's own label CHEMBL305906 ↗ |
| Known as | Merovit | ChEMBL registry synonym — accepted as the source's own label CHEMBL305906 ↗ |
| Known as | NB002 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05924906 ↗ |
| Known as | NSC-14864 | ChEMBL registry synonym — accepted as the source's own label CHEMBL305906 ↗ |
| Known as | NSC-756673 | ChEMBL registry synonym — accepted as the source's own label CHEMBL305906 ↗ |
| Known as | Search | ChEMBL registry synonym — accepted as the source's own label CHEMBL305906 ↗ |
| Known as | Steradent | ChEMBL registry synonym — accepted as the source's own label CHEMBL305906 ↗ |
| Known as | VITIS CPC Protect | “either VITIS CPC Protect® mouthwash (Mouthwash with cetylpyridinium chloride (CPC) as an anti-plaque antiseptic at a concentration of 0.07%) or mouthwash without...” NCT06251089 ↗ |
| Known as | Vitis Xtra Forte | “Cetylpyridinium chloride 0,07% (Vitis Xtra Forte©) contains cetylpyridinium chloride (C21H38ClN).” NCT04707742 ↗ |
| Action | Inhibit | “As determined in in vitro experiment, CPC was active on SARS-CoV-2 with cytotoxic and inhibitory activity” PMID 37985697 ↗ Nov 2023 |
| Modality | Small molecule | “Cetylpyridinium chloride like chlorhexidine is a quarternary ammonium salt.” NCT02644135 ↗ |
| Route | Other | “mouthwash;rinse full strength for 30 seconds with 20 ml (2/3 fl. Ounce or 4 teaspoonfuls) morning and night.” NCT00885599 ↗ |